Background
Methods
Study Population
Total (100%) | GCDFP-15 negative | GCDFP-15 positive | p | |
---|---|---|---|---|
Total | 602 | 363 (60.3%) | 239 (39.7%) | - |
HR (n = 576) | 0.034a
| |||
Negative | 175 | 116 (66.3%) | 59 (33.7%) | |
Positive | 401 | 228 (56.9%) | 173 (43.1%) | |
HER2 (n = 576) | 0.035a
| |||
Negative | 478 | 299 (62.6%) | 179 (37.4%) | |
Positive | 116 | 60 (51.7%) | 56 (48.3%) | |
Biological tumor types (n = 569) | 0.001b
| |||
HR+/HER2- | 328 | 189 (57.6%) | 139 (42.4%) | |
HR+/HER+ | 68 | 37 (54.4%) | 31 (45.6%) | |
HR-/HER2+ | 43 | 19 (44.2%) | 24 (55.8%) | |
HR-/HER2- | 130 | 96 (73.8%) | 34 (26.2%) | |
AR (n = 545) | <0.0001a
| |||
Negative | 238 | 180 (75.6%) | 58 (24.4%) | |
Positive | 307 | 149 (48.5%) | 158 (51.5%) | |
Age (n = 602) | 0.066a
| |||
< 50 years | 273 | 176 (64.5%) | 97 (35.5%) | |
> = 50 years | 329 | 187 (56.8%) | 142 (43.2%) | |
Histological type (n = 602) | 0.090b
| |||
Ductal/others | 554 | 340 (61.4%) | 214 (38.6%) | |
Lobular | 48 | 23 (47.9%) | 25 (52.1%) | |
Grading (n = 601) | <0.0001a
| |||
G1-2 | 463 | 261 (56.4%) | 202 (43.6%) | |
G3 | 138 | 102 (73.9%) | 36 (26.1%) | |
cT (n = 591) | 0.181a
| |||
cT1-2 | 395 | 230 (58.2%) | 165 (41.8%) | |
cT3-4 | 196 | 126 (64.3%) | 70 (35.7%) | |
cN (n = 583) | 0.008a
| |||
cN0 | 261 | 141 (54.0%) | 120 (46.0%) | |
cN+ | 322 | 209 (64.9%) | 113 (35.1%) |
Immunohistochemistry
Statistical evaluation
Results
GCDFP-15 expression pattern in human breast carcinomas
Association with biological tumor types and clinico-pathological factors
Morphological features of molecular apocrine carcinomas
Prognostic impact of GCDFP-15 expression
DFS | OS | |||||
---|---|---|---|---|---|---|
% events | Mean survival, years (SE) | p | % events | Mean survival, years (SE) | p | |
GCDFP-15
| 0.044 | |||||
Negative | 30.3 | 5.85 (0.24) | 19.3 | 7.07 (0.23) | ||
Positive | 25.1 | 6.67 (0.30) | 0.052 | 13.9 | 7.75 (0.27) | |
HR
| 0.013 | |||||
Negative | 35.6 | 5.53 (0.36) | 23.3 | 6.75 (0.34) | ||
Positive | 25.0 | 6.48 (0.23) | 0.004 | 19.3 | 7.67 (0.34) | |
HER2
| 0.686 | |||||
Negative | 26.3 | 6.31 (0.22) | 16.0 | 7.46 (0.21) | ||
Positive | 37.0 | 5.64 (0.40) | 0.114 | 22.3 | 7.06 (0.24) | |
Biological tumor types
| 0.084 | |||||
HR+/HER2- | 23.2 | 6.61 (0.25) | 13.7 | 7.71 (0.24) | ||
HR+/HER2+ | 33.8 | 5.86 (0.52) | 16.9 | 7.45 (0.43) | ||
HR-/HER2+ | 43.6 | 4.98 (0.60) | 30.8 | 6.23 (0.53) | ||
HR-/HER2- | 33.3 | 5.59 (0.42) | 0.011 | 21.1 | 6.86 (0.41) | |
Age
| 0.046 | |||||
< 50 years | 24.9 | 6.48 (0.28) | 12.8 | 7.79 (0.25) | ||
> = 50 years | 31.0 | 5.93 (0.26) | 0.120 | 20.8 | 7.06 (0.24) | |
Histological type
| 0.915 | |||||
Ductal/others | 28.8 | 6.15 (0.20) | 17.2 | 7.40 (0.19) | ||
Lobular | 10.0 | 6.42 (0.55) | 0.309 | 17.4 | 6.82 (0.55) | |
grading
| 0.043 | |||||
G1-2 | 26.4 | 6.42 (0.22) | 16.1 | 7.54 (0.20) | ||
G3 | 34.6 | 5.35 (0.41) | 0.005 | 20.8 | 6.70 (0.40) | |
cT
| 0.001 | |||||
cT1-2 | 20.8 | 6.90 (0.24) | 12.4 | 7.88 (0.22) | ||
cT3-4 | 43.9 | 4.93 (0.31) | <0.0001 | 26.7 | 6.65 (0.31) | |
cN
| <0.0001 | |||||
cN0 | 22.4 | 6.91 (0.28) | 11.4 | 8.12 (0.24) | ||
cN+ | 33.9 | 5.56 (0.26) | <0.0001 | 22.5 | 6.75 (0.25) |
Predictive value of GCDFP-15 expression
n | Events | % pCR | OR | 95% CI | p | |
---|---|---|---|---|---|---|
GCDFP-15
| 0.106 | |||||
Negative | 363 | 77 | 21.2 | 1 | - | |
Positive | 239 | 38 | 15.9 | 0.70 | 0.46-1.08 | |
HR
| <0.0001 | |||||
Negative | 175 | 61 | 34.9 | 1 | - | |
Positive | 401 | 45 | 11.2 | 0.24 | 0.15-0.37 | |
HER2
| <0.0001 | |||||
Negative | 478 | 77 | 16.1 | 1 | - | |
Positive | 116 | 36 | 31.0 | 2.34 | 1.48-3.72 | |
Biological tumor types
| <0.0001 | |||||
HR+/HER2- | 328 | 28 | 8.5 | 1 | - | |
HER2+ (HR+/-) | 111 | 34 | 30.6 | 4.73 | 2.70-8.28 | |
HR-/HER2- | 130 | 43 | 33.1 | 5.30 | 3.11-0.02 | |
Age
| 0.001 | |||||
< 50 years | 273 | 68 | 24.9 | 1 | - | |
> = 50 years | 329 | 47 | 14.3 | 0.50 | 0.33-0.76 | |
Histological type
| ||||||
Ductal/others | 554 | 113 | 20.4 | 1 | - | |
Lobular | 48 | 2 | 4.2 | 0.17 | 0.04-0.71 | |
Grading
| <0.0001 | |||||
G1-2 | 463 | 74 | 16.0 | 1 | - | |
G3 | 138 | 41 | 29.7 | 2.22 | 1.43-3.46 | |
cT
| 0.098 | |||||
cT1-2 | 395 | 83 | 21.0 | 1 | - | |
cT3-4 | 196 | 30 | 15.3 | 0.68 | 0.43-1.07 | |
cN
| 0.809 | |||||
cN0 | 261 | 49 | 18.8 | 1 | - | |
cN+ | 322 | 63 | 19.6 | 1.05 | 0.70-1.59 |